Category: Medications - Page 3

Healthcare System Savings: How Generic Drugs Cut U.S. Drug Costs by Hundreds of Billions

Healthcare System Savings: How Generic Drugs Cut U.S. Drug Costs by Hundreds of Billions

Finnegan O'Sullivan Jan 1 15

Generic drugs saved $482 billion in U.S. healthcare spending in 2024, making up 90% of prescriptions but just 12% of costs. Biosimilars are the next frontier in cutting drug prices - if we remove the barriers holding them back.

More Detail
Generic Drug Savings: Real Numbers and National Statistics

Generic Drug Savings: Real Numbers and National Statistics

Finnegan O'Sullivan Dec 31 11

Generic drugs saved $467 billion in the U.S. in 2024 alone - but most people don’t realize how much they’re saving. See the real numbers behind generic vs. brand-name drug costs, biosimilar growth, and why these savings are at risk.

More Detail
Reimbursement and Coding for Biosimilars: How Billing Works Under Medicare Part B

Reimbursement and Coding for Biosimilars: How Billing Works Under Medicare Part B

Finnegan O'Sullivan Dec 29 9

Biosimilars are billed differently than generics under Medicare Part B. Each has its own HCPCS code and payment rate based on its ASP plus 6% of the reference product's price. This system affects provider choices, patient costs, and adoption rates.

More Detail
Non-formulary generics: what to do when coverage is denied

Non-formulary generics: what to do when coverage is denied

Finnegan O'Sullivan Dec 27 8

When your insurance denies coverage for a generic drug, you don't have to pay full price or go without. Learn how to use the legal exceptions process to get your medication covered - with real data, step-by-step guidance, and proven strategies.

More Detail
How to Build Patient Confidence in Generic Medications: Proven Strategies Based on Research

How to Build Patient Confidence in Generic Medications: Proven Strategies Based on Research

Finnegan O'Sullivan Dec 24 12

Generic drugs save billions but many patients still distrust them. Learn research-backed ways providers and pharmacists can build confidence through clear, empathetic communication.

More Detail
Market Exclusivity Extensions: How Pharma Companies Extend Monopolies Beyond Patents

Market Exclusivity Extensions: How Pharma Companies Extend Monopolies Beyond Patents

Finnegan O'Sullivan Dec 23 12

Market exclusivity extensions let pharmaceutical companies delay generic competition long after patents expire, using regulatory tools like orphan drug and pediatric exclusivity. These mechanisms add years to monopolies, costing billions in extra healthcare spending.

More Detail
Mail-Order Pharmacy Cost Savings: Pros and Cons

Mail-Order Pharmacy Cost Savings: Pros and Cons

Finnegan O'Sullivan Dec 22 14

Mail-order pharmacies can save hundreds a year on maintenance medications through 90-day supplies and automated systems. Learn the real pros, cons, and who benefits most - plus how to switch without mistakes.

More Detail
Opioid Tolerance: Why Your Pain Medication Dose Keeps Going Up

Opioid Tolerance: Why Your Pain Medication Dose Keeps Going Up

Finnegan O'Sullivan Dec 21 13

Opioid tolerance means your body needs higher doses over time to get the same pain relief. It’s a normal biological response-not addiction-but it increases overdose risk, especially after periods of abstinence. Learn why doses rise and what to do about it.

More Detail
Warfarin and Generic Switching: What You Need to Know About INR Monitoring and Safety

Warfarin and Generic Switching: What You Need to Know About INR Monitoring and Safety

Finnegan O'Sullivan Dec 19 13

Switching from brand-name warfarin to a generic version can affect your INR levels and increase bleeding or clotting risks. Learn how to monitor safely, when to test, and what to do if your numbers change after a switch.

More Detail
How to Compare Dissolution Profiles and What They Mean for Generic and Brand Drugs

How to Compare Dissolution Profiles and What They Mean for Generic and Brand Drugs

Finnegan O'Sullivan Dec 16 14

Dissolution profile comparison ensures generic drugs release medicine the same way as brand-name versions. Learn how f2 factors, regulatory standards, and lab tests prove bioequivalence without human trials.

More Detail